Blake Hawley, D.V.M., Worldwide Director of Global Digital and Former General Manager of U.K. & Ireland, Russia, Central Eastern Europe, and Australasia at Hill’s Pet Nutrition, to Join KindredBio
SAN FRANCISCO, California. (March 24, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN) announced today that it has appointed Blake Hawley, D.V.M., as its Chief Commercial Officer. Separately, it also announced that it expects to be added to several Russell indexes on March 31, 2014.
Dr. Hawley previously served as the General Manager of Australasia; Regional General Manager of Russia and Central Eastern Europe (consisting of 22 countries); and Managing Director of the United Kingdom and Ireland for Hill’s Pet Nutrition, a division of Colgate-Palmolive. His experience includes ten years of profit and loss responsibilities in these territories, with consistent double-digit annual revenue growth in each of the ten years. He oversaw products competing in the arthritis, dermatology, obesity, gastrointestinal, urinary, and cancer markets, among others. Dr. Hawley holds an M.B.A. from University of Kansas and a D.V.M. from North Carolina State University.
Dr. Hawley also has background in e-commerce, data analytics, and social media and most recently served as Worldwide Director of Global Digital for Hill’s Pet Nutrition.
Richard Chin, Chief Executive Officer of KindredBio, stated, “We are very excited to welcome Blake, with experience in therapeutics markets, consumer marketing, profit and loss responsibilities, international markets, and social marketing–key commercial areas important to KindredBio, and are especially fortunate to have found a marketing executive who is also a veterinarian.”
Dr. Hawley stated, “I am honored to be joining the KindredBio team, dedicated to the mission of saving lives and eliminating pain and suffering in our best friends.”
Separately, KindredBio announced that Russell Investments has announced inclusion of KindredBio in the preliminary list of IPO additions to the Russell 2000 Index, Russell 3000 Index, Russell Global Index, and Russell Microcap Index as part of Russell Investments’ quarterly index adjustment on March 31, 2014. Membership in the Russell Indexes means KindredBio’s automatic inclusion in the appropriate growth and value style indexes.
About Kindred Biosciences
Kindred Biosciences is a development stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company’s lead product candidates are CereKin™ (diacerein) for the treatment of osteoarthritis pain and inflammation in dogs, AtoKin™ (fexofenadine) for the treatment of atopic dermatitis in dogs, and SentiKin™ (flupirtine) for the treatment of post-operative pain in dogs.
Forward-looking statements in this news release involve inherent risks and uncertainties and a number of important factors could cause actual results to differ materially from those contained in such forward-looking statements. These factors include, but are not limited to uncertainties associated with drug development and regulatory review process and the factors described in KindredBio’s Annual Report on Form 10-k for the fiscal year ended December 31, 2013 filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date of this news release.